https://www.selleckchem.com/pr....oducts/z-ietd-fmk.ht
The real-world data of glecaprevir/pibrentasvir (GLE/PI therapy for patients with chronic hepatitis C virus (HCV) genotype 2 infection remained limited. We aimed to evaluate the possible predictors of virological failure and side effects of GLE/PIB therapy for chronic genotype 2 HCV-infected patients in a real-world setting. A total of 326 compensated HCV genotype 2 patients treated with GLE/PIB 12 weeks for cirrhotic patients (n=56) and 8 weeks for non-cirrhotic patients (n=27 were enrolled. The sustained virological response 12
Like
Comment
Share
